Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Solid Tumors 1Colorectal Cancer Metastatic 1

Interventions

aflibercept 6Oxaliplatin 3Leucovorin 3Irinotecan 3Fluorouracil 2Capecitabine 2Bevacizumab 2trifluridine tipiracil drug combination 1raltitrexed 1monoclonal antibody YYB-101 1masitinib 1atezolizumab 1Vemurafenib 1Panitumumab 1Nivolumab 1IFL protocol 1HMPL-013 1Ethiodized Oil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Cancer Metastatic × monoclonal antibody YYB-101 × Clear all
NCT04368507 2022-11-14

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

CellabMED

Phase 1/2 Completed
35 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡